Get the Stockscreener App
3.11
3.32%
0.10
Lipocine Inc stock is traded at $3.11, with a volume of 36,127.
It is up +3.32% in the last 24 hours and down -4.60% over the past month.
Lipocine Inc is a clinical-stage biopharmaceutical company, that is engaged in research and development for the delivery of drugs using its proprietary delivery technology. Its principal operation is to provide oral delivery solutions for existing drugs. Lipocine develops its drug candidates or it develops drug candidates on behalf of or in collaboration with corporate partners. The company's product TLANDO is an oral testosterone replacement therapy ("TRT"). It also has other products in the pipeline such as LPCN 1144, TLANDO, TLANDO XR, LPCN 1148, LPCN 1107, LPCN 1154, and LIP'RAL7 Technology. The Company has a single reportable segment, research, and development for the delivery of drugs using its proprietary delivery technology.
See More
Previous Close:
$3.01
Open:
$3.045
24h Volume:
36,127
Relative Volume:
0.77
Market Cap:
$16.85M
Revenue:
-
Net Income/Loss:
$-16.35M
P/E Ratio:
-1.0197
EPS:
-3.05
Net Cash Flow:
$-11.88M
1W Performance:
+2.74%
1M Performance:
-4.60%
6M Performance:
-7.99%
1Y Performance:
-16.17%
1-Day Range:
$2.97
$3.1385
1-Week Range:
$2.91
$3.14
52-Week Range:
$2.6838
$6.1683
Lipocine Inc Stock (LPCN) Company Profile
Name
Lipocine Inc
Sector
Industry
Phone
801 994 7383
Address
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Compare LPCN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.11 | 16.31M | 0 | -16.35M | -11.88M | -3.05 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.12 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
589.48 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
454.38 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
660.00 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
313.67 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-24-21 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-20 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Jan-12-18 | Reiterated | H.C. Wainwright | Buy |
| Jan-11-18 | Downgrade | Canaccord Genuity | Buy → Hold |
| Dec-08-17 | Resumed | H.C. Wainwright | Buy |
| Oct-07-16 | Initiated | H.C. Wainwright | Buy |
| Jul-22-15 | Initiated | ROTH Capital | Buy |
| Jun-23-15 | Initiated | Canaccord Genuity | Buy |
View All
Lipocine Inc Stock (LPCN) Latest News
Lipocine Inc. stock volume spike explainedPortfolio Growth Summary & Weekly Top Gainers Alerts - Newser
Will Lipocine Inc. price bounce be sustainableGap Up & Smart Allocation Stock Tips - Newser
Visualizing Lipocine Inc. stock with heatmapsMarket Activity Summary & Free Daily Entry Point Trade Alerts - Newser
Lipocine Inc. Flashes Buy Signal on Multi Timeframe ChartJuly 2025 Update & Fast Momentum Entry Tips - beatles.ru
Combining price and volume data for Lipocine Inc.2025 Price Targets & Weekly High Return Stock Opportunities - Newser
Advanced analytics toolkit walkthrough for Lipocine Inc.Portfolio Growth Summary & Long-Term Investment Growth Plans - Newser
Can technical indicators confirm Lipocine Inc.’s reversal2025 Pullback Review & Reliable Price Breakout Alerts - Newser
Tools to monitor Lipocine Inc. recovery probabilityJuly 2025 Final Week & Real-Time Volume Spike Alerts - Newser
What the charts say about Lipocine Inc. todayJuly 2025 Rallies & Low Drawdown Investment Strategies - Newser
Is Lipocine Inc. stock reversal real or fake2025 Risk Factors & Real-Time Stock Entry Alerts - Newser
Intraday pattern recognizer results for Lipocine Inc.Rate Hike & Community Verified Trade Signals - Newser
Visual analytics tools that track Lipocine Inc. performanceQuarterly Profit Summary & Real-Time Buy Zone Alerts - Newser
Published on: 2025-08-19 14:03:04 - Newser
Relative strength of Lipocine Inc. in sector analysisEarnings Recap Report & AI Driven Stock Reports - Newser
How to read the order book for Lipocine Inc.Day Trade & Low Risk Investment Opportunities - Newser
Strategies to average down on Lipocine Inc.July 2025 Momentum & Fast Gain Swing Alerts - Newser
Is There Enough Volume to Lift Lipocine Inc.Bull Run & Fast Entry High Yield Tips - beatles.ru
Real time alert setup for Lipocine Inc. performanceEarnings Beat & Expert Curated Trade Setups - Newser
Lipocine Inc. stock trend outlook and recovery pathWeekly Trade Report & Detailed Earnings Play Strategies - Newser
Multi factor analysis applied to Lipocine Inc.Portfolio Performance Report & Weekly Breakout Stock Alerts - Newser
What machine learning models say about Lipocine Inc.July 2025 PreEarnings & Accurate Intraday Trade Tips - Newser
What makes Lipocine Inc. stock price move sharplyInsider Buying & Expert Verified Stock Movement Alerts - Newser
Moving Average Trends for Lipocine Inc. Stock: What They IndicateQuarterly Market Review & Long Hold Capital Preservation Plans - Newser
Pattern recognition hints at Lipocine Inc. upsideChart Signals & Safe Entry Momentum Tips - Newser
Is Lipocine Inc. vulnerable to short sellersJuly 2025 Sector Moves & Risk Controlled Daily Trade Plans - thegnnews.com
When is the best time to exit Lipocine Inc.2025 Bull vs Bear & AI Forecasted Stock Moves - Newser
Lipocine Inc Stock (LPCN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.94%
1.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):